M J Arranz

Summary

Affiliation: National Institute for Medical Research
Country: UK

Publications

  1. ncbi request reprint Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response
    M J Arranz
    Department of Psychological Medicine, Institute of Psychiatry, London, UK
    Schizophr Res 32:93-9. 1998
  2. ncbi request reprint Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine
    M J Arranz
    Department of Psychological Medicine, Institute of Psychiatry, Denmark Hill, London, UK
    Neurosci Lett 217:177-8. 1996
  3. ncbi request reprint 5-HT2A receptor and bipolar affective disorder: association studies in affected patients
    M J Arranz
    Department of Psychological Medicine, Institute of Psychiatry, London, UK
    Neurosci Lett 224:95-8. 1997
  4. ncbi request reprint Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine
    M J Arranz
    Department of Psychological Medicine, Institute of Psychiatry, Denmark Hill, London, UK
    Mol Psychiatry 3:61-6. 1998
  5. ncbi request reprint Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response
    M J Arranz
    Department of Psychiatric Medicine, Institute of Psychiatry, London, UK
    Pharmacogenetics 8:481-4. 1998
  6. ncbi request reprint Association analysis between dopamine receptor genes and bipolar affective disorder
    T Li
    Department of Psychological Medicine, The Institute of Psychiatry, London, UK
    Psychiatry Res 86:193-201. 1999
  7. ncbi request reprint Association between clozapine response and allelic variation in the 5-HT2C receptor gene
    M S Sodhi
    Department of Psychological Medicine, Institute of Psychiatry, London, UK
    Neuroreport 7:169-72. 1995
  8. ncbi request reprint Choline acetyltransferase variants and their influence in schizophrenia and olanzapine response
    D Mancama
    Section of Clinical Neuropharmacology, Department of Psychological Medicine, Institute of Psychiatry, DeCrespigny Park, Denmark Hill, London, England
    Am J Med Genet B Neuropsychiatr Genet 144:849-53. 2007
  9. ncbi request reprint Investigation of promoter variants of the histamine 1 and 2 receptors in schizophrenia and clozapine response
    D Mancama
    Section of Clinical Neuropharmacology, Department of Psychological Medicine, Institute of Psychiatry, De Crespigny Park, London SE5 8AF, UK
    Neurosci Lett 333:207-11. 2002
  10. ncbi request reprint Apolipoprotein-E gene variants associated with cardiovascular risk factors in antipsychotic recipients
    D Clark
    Department of Psychological Medicine, Institute of Psychiatry, King s College, 1, Windsor Walk, PO51, London SE5 8AF, UK
    Eur Psychiatry 24:456-63. 2009

Collaborators

Detail Information

Publications23

  1. ncbi request reprint Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response
    M J Arranz
    Department of Psychological Medicine, Institute of Psychiatry, London, UK
    Schizophr Res 32:93-9. 1998
    ..Statistical analysis of extreme responders showed a clearer association of the 102-T/C with clozapine response. These results reinforce the hypothesis and strengthen the candidacy of these receptors as important therapeutic targets...
  2. ncbi request reprint Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine
    M J Arranz
    Department of Psychological Medicine, Institute of Psychiatry, Denmark Hill, London, UK
    Neurosci Lett 217:177-8. 1996
    ..An association was found between the allele Tyr452 and poor clinical response...
  3. ncbi request reprint 5-HT2A receptor and bipolar affective disorder: association studies in affected patients
    M J Arranz
    Department of Psychological Medicine, Institute of Psychiatry, London, UK
    Neurosci Lett 224:95-8. 1997
    ..No strong associations were found between any of these polymorphisms and bipolar affective disorder. Genetic variation at the 5-HT2A receptor gene does not play a major role in the pathogenesis of the disorder...
  4. ncbi request reprint Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine
    M J Arranz
    Department of Psychological Medicine, Institute of Psychiatry, Denmark Hill, London, UK
    Mol Psychiatry 3:61-6. 1998
    ..These results provide further evidence suggesting that genetic variation at 5-HT2A receptors may influence clozapine response and strengthen the candidacy of these receptors as important therapeutic targets...
  5. ncbi request reprint Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response
    M J Arranz
    Department of Psychiatric Medicine, Institute of Psychiatry, London, UK
    Pharmacogenetics 8:481-4. 1998
    ....
  6. ncbi request reprint Association analysis between dopamine receptor genes and bipolar affective disorder
    T Li
    Department of Psychological Medicine, The Institute of Psychiatry, London, UK
    Psychiatry Res 86:193-201. 1999
    ..We also report a novel, rare one-repeat variant of the DRD4 exon 3 VNTR repeat in Chinese populations, which appears to be absent in Caucasians and is not associated with disease...
  7. ncbi request reprint Association between clozapine response and allelic variation in the 5-HT2C receptor gene
    M S Sodhi
    Department of Psychological Medicine, Institute of Psychiatry, London, UK
    Neuroreport 7:169-72. 1995
    ..There was no association between schizophrenia and the 5-HT2Cser allele, but our results indicate that the 5-HT2C receptor may contain the major site of action through which clozapine mediates its antipsychotic effects...
  8. ncbi request reprint Choline acetyltransferase variants and their influence in schizophrenia and olanzapine response
    D Mancama
    Section of Clinical Neuropharmacology, Department of Psychological Medicine, Institute of Psychiatry, DeCrespigny Park, Denmark Hill, London, England
    Am J Med Genet B Neuropsychiatr Genet 144:849-53. 2007
    ....
  9. ncbi request reprint Investigation of promoter variants of the histamine 1 and 2 receptors in schizophrenia and clozapine response
    D Mancama
    Section of Clinical Neuropharmacology, Department of Psychological Medicine, Institute of Psychiatry, De Crespigny Park, London SE5 8AF, UK
    Neurosci Lett 333:207-11. 2002
    ....
  10. ncbi request reprint Apolipoprotein-E gene variants associated with cardiovascular risk factors in antipsychotic recipients
    D Clark
    Department of Psychological Medicine, Institute of Psychiatry, King s College, 1, Windsor Walk, PO51, London SE5 8AF, UK
    Eur Psychiatry 24:456-63. 2009
    ..These associations warrant prospective study to assess interaction between APOE gene variants and the propensity of antipsychotics to induce cardiovascular risk factors...
  11. ncbi request reprint Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's disease
    A J Makoff
    Department of Psychological Medicine, Institute of Psychiatry, London, UK
    Pharmacogenetics 10:43-8. 2000
    ..5 kb 3' to DRD2. This polymorphism may be in linkage disequilibrium with a mutation in DRD2 or a nearby gene that predisposes to drug-induced hallucinations which occur later in the course of idiopathic Parkinson's disease...
  12. ncbi request reprint Neurotransmitter receptor variants and their influence on antipsychotic treatment (Review))
    M J Arranz
    Clinical Neuropharmacology, Institute of Psychiatry, London SE5 8AF, UK
    Int J Mol Med 7:27-30. 2001
    ..Recent advances indicate that this goal is achievable in the near future. The scope of this communication is to review all the recent findings in psychopharmacogenetics leading to the individualization of treatment...
  13. ncbi request reprint 5-HT2A and 5-HT2C receptor polymorphisms and psychopathology in late onset Alzheimer's disease
    C Holmes
    Department of Neuroscience, Institute of Psychiatry, De Crespigny Park, London SE5 8AF, UK
    Hum Mol Genet 7:1507-9. 1998
    ....
  14. ncbi request reprint No association between ADRA2A polymorphisms and schizophrenia
    D A Clark
    Clinical Neuropharmacology, Division of Psychological Medicine, Institute of Psychiatry, King s College, London, United Kingdom
    Am J Med Genet B Neuropsychiatr Genet 144:341-3. 2007
    ..No associations were evident, suggesting no influence for these SNPs in susceptibility to schizophrenia...
  15. ncbi request reprint Polymorphisms in the genes for mGluR types 7 and 8: association studies with schizophrenia
    A A Bolonna
    Department of Psychological Medicine, Section of Clinical Neuropharmacology, Institute of Psychiatry, Denmark Hill, London SE5 8AF, UK
    Schizophr Res 47:99-103. 2001
    ..Both variants, present at high frequencies, failed to demonstrate any significant association with schizophrenia (mGluR7 [Tyr433Phe] allele: P=0.33; genotype: P=0.63; mGluR8 [2846-C/T] allele: P=0.72; genotype: P=0.63)...
  16. ncbi request reprint Genetic strategies for the personalization of antipsychotic treatment
    R W Kerwin
    Institute of Psychiatry, Windsor Walk, London SE5 8AF, UK
    Expert Rev Mol Diagn 1:275-80. 2001
    ..The scope of this article is to review recent advances of pharmacogenetic research on antipsychotic drugs and the strategies under development for the individualization of treatment...
  17. ncbi request reprint Applications of pharmacogenetics in psychiatry: personalisation of treatment
    M J Arranz
    Clinical Neuropharmacology, Institute of Psychiatry, Denmark Hill, London SE5 8AF, UK
    Expert Opin Pharmacother 2:537-42. 2001
    ..In addition to providing the first evidence that treatment response can be predicted by looking at a core of key genes, these studies illustrate the feasibility of individualisation of psychiatric treatment...
  18. ncbi request reprint Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia
    D Mancama
    Section of Clinical Neuropharmacology, Department of Psychological Medicine, Institute of Psychiatry, De Crespigny Park, London, England, UK
    Am J Med Genet B Neuropsychiatr Genet 119:2-6. 2003
    ..These results provide evidence in support of altered muscarinic 1 receptor expression in schizophrenia, though further work is needed to corroborate these findings...
  19. ncbi request reprint Pharmacogenetics for the individualization of psychiatric treatment
    M J Arranz
    Section of Clinical Neuropharmacology, Institute of Psychiatry, London, England
    Am J Pharmacogenomics 1:3-10. 2001
    ....
  20. ncbi request reprint Pharmacogenomics--can genetics help in the care of psychiatric patients?
    A A Bolonna
    Clinical Neuropharmacology, Division of Psychological Medicine, Institute of Psychiatry, KCL, London, UK
    Int Rev Psychiatry 16:311-9. 2004
    ....
  21. ncbi request reprint Neurotransmitter-related genes and antipsychotic response: pharmacogenetics meets psychiatric treatment
    M J Arranz
    Department of Psychological Medicine, Institute of Psychiatry, London, UK
    Ann Med 32:128-33. 2000
    ..Future psychiatric prescription will include the genetic characterization of neurotransmitter receptors for the selection of the most beneficial drug according to the individual's pharmacogenetic profile...
  22. ncbi request reprint Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research
    M J Arranz
    Clinical Neuropharmocology, Division of Psychological Medicine, Institute of Psychiatry King s College, London, UK
    Mol Psychiatry 12:707-47. 2007
    ..Current knowledge on genetic prediction of drug metabolic status, general response and drug-induced side effects will be reviewed and future pharmacogenomic and epigenetic research will be discussed...
  23. ncbi request reprint Advances in the pharmacogenetic prediction of antipsychotic response
    M J Arranz
    Clinical Neuropharmacology, Institute of Psychiatry, Denmark Hill, London SE5 8AF, UK
    Toxicology 192:33-5. 2003
    ..It is expected that over the next decade these advances are introduced into clinical practice and will help to tailor psychiatric treatment to the patient's individual needs...